Back to search

Virginia Commonwealth University

KPT-330 synergizes with everolimus to reduce mTORC1-overactive basal-like triple-negative breast cancer brain metastasis burden

Abstract

dc:description.abstract

Triple-negative breast cancer (TNBC), a highly metastatic breast cancer subtype, accounts for approximately 20% of all breast cancer diagnoses. Basal-like TNBC is notably difficult to treat due to the lack of actionable drug targets such as estrogen and progesterone receptors, as well as HER2. Due to the deficiency in TNBC-targeting drugs that are able to cross the blood-brain barrier (BBB) for breast-to-brain metastasis, there is a need to develop novel BBB-permeable treatments. After preliminary testing, KPT-330 (XPO1 inhibitor) and everolimus (FKBP1A/mTOR inhibitor) were selected as drug candidates for this study. Patient-derived xenograft (PDX) models for in vitro and in vivo studies were chosen based on the relative transcriptomic and proteomic expression of XPO1 and FKBP1A. KPT-330, everolimus, and KPT-330 + everolimus were assessed in NSG mice with mammary gland tumors or metastases. KPT-330 + everolimus significantly reduced an mTORC1-overactive PDX primary tumor burden compared to single agents and vehicle control, whereas an mTORC1-underactive PDX primary tumor burden was not significantly reduced upon treatment. Further testing of the affected PDX determined that the metastasis burden in the brain and ovaries was significantly reduced upon treatment with KPT-330 + everolimus. Therefore, the proposed treatment may be effective in improving the outcome of patients suffering from mTORC1-overactive TNBC surgically non-resectable metastases. FKBP1A expression could serve as a biomarker for future treatment selection for TNBC.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
Thesis
Discipline thesis:degree_discipline
Biology

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Valentine, Aaron D
  • 0000-0003-1856-7411
Contributors dc:contributor
  • J. Chuck Harrell, PhD
  • Tomasz Kordula, PhD
  • Erich Damm, PhD
  • Jason Newton, PhD

Subjects

dc:subject × 6

Rights

dc:rights
Statement dc:rights
  • © Aaron D. Valentine 2023

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
Virginia Commonwealth University
Base URL
scholarscompass.vcu.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Valentine, Aaron D; 0000-0003-1856-7411. KPT-330 synergizes with everolimus to reduce mTORC1-overactive basal-like triple-negative breast cancer brain metastasis burden. Thesis thesis, https://doi.org/10.25772/0S5B-9085